#NEPAD

[jobskenyaplace]

PROVISION OF A COMPREHENSIVE MEDICAL INSURANCE COVER AND GENERAL INSURANCE COVERS FOR NEPAD/APRM KENYA SECRETARIAT 2024

NEPAD/APRM KENYA SECRETARIAT [NAKS] TENDER AUGUST 2024  TENDER NOTICE              INVITATION TO TENDER REF: NO. NAKS/T/01/2024-2025  PROVISION OF A COMPREHENSIVE MEDICAL INSURANCE COVER AND GENERAL INSURANCE COVERS FOR NEPAD/APRM KENYA SECRETARIAT The NEPAD/APRM Kenya Secretariat [NAKS], a Semi-Autonomous Government Agency under the State Department of Planning located at LIAISON HOUSE, 4TH…

[touchaheartnews]

Basil Omiyi Retires as Stanbic IBTC Holdings Chairman

Mr Basil Omiyi has retired as Chairman of Stanbic IBTC Holdings after seven years of heading the group. He joined Stanbic IBTC in March 2015 as a Non-Executive Director before becoming the group’s chair on May 15, 2017, replacing Atedo Peterside. According to the press release by the group, a new board chairman has been approved and will be announced at a future date after receiving regulatory…

[iweb-rdc001]

Kinshasa s'apprête à accueillir au mois d'octobre 2023 le Salon de l’innovation et de la SADC

Kinshasa, capitale de la République Démocratique du Congo accueillira au prochain mois de cette année le Salon de l’innovation et de transformation rurale de la Communauté de développement de l’Afrique australe (SADC) en sigle. Cette annonce a été faite par le ministre de l’agriculture lors de son intervention à la 113e réunion du conseil des ministres qui a eu lieu le vendredi 15 septembre…

[developmentinformationday]

Letter from the President of the General Assembly – New Partnership for Africa’s Development – NEPAD.

Interactive multi-stakeholder dialogue on the review of the implementation of commitments made towards Africa's development - General Assembly, 77th session.

[thxnews]

Germany Commits €10 Million to Boost Infrastructure Development in Africa

  Strengthening Africa's Infrastructure: Germany's Support

Germany Provides €10 Million to NEPAD-IPPF Special Fund Berlin, Germany - In a significant boost to regional infrastructure development in Africa, the German Federal Ministry for Economic Cooperation and Development (BMZ) has pledged €10 million to replenish the NEPAD – Infrastructure Project Preparation Facility (NEPAD-IPPF) Special Fund. The African Development Bank, in partnership with KfW on behalf of BMZ, announced the agreement, solidifying their commitment to enhancing Africa's infrastructure.   Germany's Focus on Sustainable and Climate-Smart Infrastructure The agreement, signed in Berlin, signifies Germany's dedication to supporting NEPAD-IPPF's priorities, particularly in green and climate-smart infrastructure. The funding will also align with the second Priority Action Plan of the Programme for Infrastructure Development in Africa (PIDA-PAP 2) for the period 2021-2030. By bolstering the NEPAD-IPPF Special Fund, Germany aims to contribute to Africa's transformation under the Africa Continental Free Trade Area, facilitating intra- and extra-African trade.   Strengthening Collaboration for Sustainable Development Goals Christoph Tiskens, Director at KfW, expressed his satisfaction with the partnership, highlighting its focus on climate change, gender equality, Agenda 2063, and the Sustainable Development Goals. He praised the achievements of NEPAD-IPPF while acknowledging the increasing demands faced by the fund. As a key partner of the African Development Bank, KfW remains committed to supporting initiatives that drive economic growth and reduce poverty.   African Development Bank's Mission Amid Global Challenges Hassatou N'Sele, Vice-President and Chief Financial Officer of the African Development Bank, emphasized the crucial role of partners like Germany in enabling the Bank to fulfill its development mission. The replenishment of the NEPAD-IPPF Special Fund will empower the Bank to better assist its clients, facilitating economic potential realization through increased infrastructure investments. N'Sele stressed the importance of green growth, inclusion, and job creation as key drivers for Africa's development.   Strengthening Infrastructure Development for Bankable Projects Mike Salawou, Director for Infrastructure and Urban Development at the African Development Bank, lauded Germany's contribution as a testament to the Bank's leadership in infrastructure development and financing. Salawou highlighted the NEPAD-IPPF Special Fund's catalytic role in driving infrastructure development in Africa. With the additional resources, the Fund can effectively prepare bankable projects, attracting both public and private sector financing to further bolster the continent's infrastructure.  

About NEPAD-IPPF: Advancing Sustainable Infrastructure in Africa

The New Partnership for Africa's Development Infrastructure Project Preparation Facility (NEPAD-IPPF) serves as a multi-donor Special Fund, hosted by the African Development Bank. As a leading project preparation facility in Africa, NEPAD-IPPF plays a pivotal role in providing technical and financial assistance for the preparation of regional infrastructure projects and programs. The Fund's mandate focuses on spurring sustainable infrastructure development across the African continent by preparing viable and high-quality regional projects in sectors such as energy, transport, information and communication technology, and transboundary water resources. Participation in the Special Fund is open to donors, institutional funds, and other specialized infrastructure funds.   Sources: THX News & African Development Bank Group. Read the full article

[konradnews]

Participation in the 8th Africa Infrastructure Development Program (PIDA) Week: Successful Launch of OSBP Status Report Jointly Prepared with AUDA-NEPAD ｜ News & PR

summary Conference Title: 8th Program for Infrastructure Development in Africa (PIDA) Week at the headquarters of the African Union (AU) Date: November 25-28, 2024 Organizers: African Union Development Agency (AUDA-NEPAD), African Union Commission (AUC), Government of Ethiopia Supported by: African Development Bank (AfDB), United Nations Economic Commission for Africa (UNECA), AfCFTA Secretariat,…

[akeliciousmedia]

Civil Society Group Demands Reversal of NEPAD Appointment Over Alleged Gender Bias

Concerned Civil Society Organizations Of Katsina State, has criticized president Bola Ahmed Tinubu following the alledged marginalization of women in his cabinet. The group in a press statement issued to journalists in Kaduna on Tuesday signed by its chairman, Comrade Adamu Ibrahimah Matazu, lamented that the alledged marginalization fall short of global best practices where women are encouraged…

[rovingnaija]

President Tinubu Appoints New Excos Into NUC, NERDC, NEPAD, Reappoints Fatima Shinkafi At SMDF

President Bola Tinubu has announced the appointment of chief executive officers for the National Universities Commission (NUC), the Nigerian Educational Research and Development Council (NERDC) and the New Partnership for Africa Development (NEPAD). The President also approved the renewal of the appointment of Fatima Umaru Shinkafi as the executive secretary of the Solid Minerals Development…

[saynaija]

President Tinubu Announces Key Appointments Into NUC, NERDC, NEPAD, Renews The Appointment Of Fatima Shinkafi In SMDF

President Tinubu Announces Key Appointments Into NUC, NERDC, NEPAD, Renews The Appointment Of Fatima Shinkafi In SMDF President Bola Tinubu has announced the appointment of chief executive officers for the National Universities Commission (NUC), the Nigerian Educational Research and Development Council (NERDC) and the New Partnership for Africa Development (NEPAD). The President also approved…

[lagmennet]

Tinubu Appoints CEOs for NUC, SMDF, NERDC, NEPAD

President Bola Tinubu has chosen CEOs of the National Universities Commission (NUC), the Nigerian Educational Research and Development Council (NERDC), and the New Partnership for Africa Development (NEPAD). According to a statement issued Friday by presidential spokesman Bayo Onanuga. He named Abdullahi Yusuf Ribadu, a visiting lecturer at the NUC, as the organization’s Executive…

[latestmarketresearchnews]

In Vitro Diagnostics (IVD) Industry Sales, Demand, Regional Outlook And Supply Chain Analysis till 2030

The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.

Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.

The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.

End-use Segmentation Insights:

Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.

In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

In Vitro Diagnostics (IVD) Industry Growth Analysis & Forecast Research Report, 2030

The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.

Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.

The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.

End-use Segmentation Insights:

Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.

In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[iweb-rdc001]

Kinshasa s'apprête à accueillir au mois d'octobre 2023 le Salon de l’innovation et de la SADC

Kinshasa, capitale de la République Démocratique du Congo accueillira au prochain mois de cette année le Salon de l’innovation et de transformation rurale de la Communauté de développement de l’Afrique australe (SADC) en sigle. Cette annonce a été faite par le ministre de l’agriculture lors de son intervention à la 113e réunion du conseil des ministres qui a eu lieu le vendredi 15 septembre…

[tamanna31]

New Study: 2024-2030 In Vitro Diagnostics Market Trend and Forecast Report

In Vitro Diagnostics Industry Overview

The global in vitro diagnostics (IVD) market size was estimated at USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. The growth can be attributed to increasing adoption of IVD owing to a rise in the incidence of infectious and chronic diseases. The development of automated IVD systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnoses is expected to fuel market growth. The rising number of IVD products being launched by key players is also fueling market growth. For instance, in November 2023, ARUP Laboratories received a CE mark from EU-IVDR for AAV5 DetectCDx, a companion diagnostic to select the eligibility of severe hemophilia A-affected patients for BioMarin’s new gene therapy, Roctavian.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market

Technological advancements in terms of accuracy, portability, and cost-effectiveness are expected to be one of the high-impact rendering drivers of this market. Introduction of novel and highly accurate clinical laboratory tests is boosting the adoption of novel IVD tests worldwide. In June 2023, Toray Industries, Inc. received marketing approval from Japan’s Ministry of Health, Labour and Welfare for its Toray APOA2-iTQ used to diagnose pancreatic cancer. Moreover, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory Traumatic Brain Injury (TBI) blood test in the U.S. Increasing approvals of IVD tests for life-threatening diseases are expected to create new opportunities in the untapped market.

Key players in the market undertake various strategies to strengthen their position and offer their customers diverse, technologically advanced & innovative products. New product launches and partnerships are the most prominently adopted by companies to attract more customers. For instance, in March 2023, BD received 510(k) clearance for BD Vaginal Panel on the BD COR System to detect infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) formed a partnership with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for the diagnosis of cancer in Northern Ireland.

Favorable initiatives undertaken by government and non-government bodies to improve overall healthcare services are anticipated to increase market growth. In October 2023, the WHO published the Essential Diagnostics List (EDL), a comprehensive list of IVD products that helps countries make decisions regarding diagnostic tools. It provides evidence-based recommendations and ensures the accessibility of essential products for target people. Moreover, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to increase access to diagnostic tests across Africa. Such initiatives are expected to boost market growth.

A rise in the geriatric population and growth in knowledge regarding early testing have led to a surge in the number of regular check-ups, as a majority of deaths due to infections and chronic conditions occur in the population aged over 75 years. As per the Office for Budget Responsibility, UK, healthcare costs have risen exponentially, which can create economic pressure on nations with rapidly growing geriatric population. However, this expenditure is anticipated to translate positively for the IVD industry, driving market growth.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global point of care infectious disease testing market size was valued at USD 11.40 billion in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2030.

• The global transplant diagnostics market size was valued at USD 5.97 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2030.

Key Companies & Market Share Insights

Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.

Llusern Scientific, Biocartis Group NV, ARUP Laboratories, Veracyte, and Exact Sciences Corp are some of the emerging market participants in the market. Emerging companies are actively involved in developing novel and accurate IVD testing products to improve overall health services. Moreover, these companies are collaborating with research institutes, government bodies, and global leaders to increase the range of their products in potential markets.

Key In Vitro Diagnostics (IVD) Companies

Abbott

bioMérieux SA

QuidelOrtho Corporation

Siemens Healthineers AG

Bio-Rad Laboratories, Inc.

Qiagen

Sysmex Corporation

Charles River Laboratories

Quest Diagnostics Incorporated

Agilent Technologies, Inc.

Danaher Corporation

BD

F. Hoffmann-La Roche Ltd

Recent Developments

In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients

In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte

In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors

In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure

In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

[thecountydiary]

Makueni Celebrated for Leadership and Innovation at Peer Review Summit

Makueni County received high praise for its exceptional public participation governance model at the inaugural National County Peer Review Mechanism Summit held in Nairobi. The recognition came from the New Partnership for Africa’s Development (NEPAD)/African Peer Review Mechanism (APRM) Kenya Secretariat. The County Peer Review Mechanism (CPRM) is a voluntary self-assessment initiative for…

[konradnews]

President Tanaka meets with Dr. Bekele-Thomas, Director General of the African Union Development Agency (AUDA-NEPAD) ｜ News & PR

JICA President Akihiko Tanaka met with Ms. Nardos Bekele-Thomas, CEO of the African Union Development Agency (AUDA-NEPAD), at JICA headquarters on October 2. Meeting with AUDA-NEPAD delegation including Secretary At the beginning of the meeting, President Tanaka thanked JICA for its cooperation with AUDA-NEPAD, which has resulted in the areal expansion of JICA’s cooperation on the African…